- Home
- EWBC vs BBIO Comparison
EWBC vs BBIO Comparison
Compare EWBC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EWBC | BBIO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 15.9B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EWBC | BBIO |
|---|---|---|
| Price | $128.02 | $68.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 25 |
| Target Price | ★ $131.14 | $86.33 |
| AVG Volume (30 Days) | 634.2K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 5.21 | N/A |
| Revenue | $55,316,000.00 | ★ $502,076,000.00 |
| Revenue This Year | $13.49 | $89.45 |
| Revenue Next Year | $5.78 | $73.78 |
| P/E Ratio | $24.65 | ★ N/A |
| Revenue Growth | 3.12 | ★ 126.26 |
| 52 Week Low | $92.67 | $48.78 |
| 52 Week High | $137.47 | $93.42 |
Technical Indicators
Market Signals| Indicator | EWBC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 22.87 |
| Support Level | $126.11 | $66.58 |
| Resistance Level | $136.09 | $70.49 |
| Average True Range (ATR) | 2.14 | 2.45 |
| MACD | -0.01 | -0.83 |
| Stochastic Oscillator | 40.21 | 10.39 |
Price Performance
Historical ComparisonAbout EWBC East West Bancorp Inc.
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.